AngioDynamics Reports Strong Q3 2026 Performance Amid Margin Pressures
The health‑care equipment specialist AngioDynamics Inc. (NASDAQ: ANGO) announced its financial results for the third quarter of fiscal year 2026, ending February 28, 2026, on April 2 2026. The company, headquartered in Latham, New York, continues to focus on therapeutic and diagnostic devices used by interventional physicians for peripheral vascular and other non‑coronary diseases.
Revenue and Sales Growth
AngioDynamics reported net sales of $78.4 million, an 8.9 % increase on a pro‑forma basis versus the same period a year earlier. The growth was predominantly driven by the Med Tech segment, which expanded 19 % to $37.3 million. Within Med Tech, the mechanical thrombectomy portfolio—including the AlphaVac and AngioVac systems—contributed significantly, while the NanoKnife platform experienced accelerated uptake in prostate‑related procedures after recent CPT code updates.
The Med Device segment remained largely flat, delivering $41.1 million in net sales—a 1.1 % year‑over‑year increase. Gross margin on a GAAP basis stood at 52.9 %.
Earnings Per Share and Guidance
The company’s earnings per share for the quarter fell into the negative, with a loss of $0.19 per share compared to $0.11 per share loss recorded in the corresponding period last year. On a non‑GAAP basis, EPS was $‑0.07, narrowly beating analyst expectations by $0.04.
Despite the quarterly loss, AngioDynamics raised its full‑year 2026 guidance. Pro‑forma adjusted EBITDA is now projected at $10 million to $12 million, and net sales guidance has been increased to $313.5 million–$315.5 million.
Investor and Analyst Reactions
The earnings release spurred a mixed reaction in the market. While the company’s revenue surpassed expectations, the continued decline in margins and the negative EPS have prompted several analysts to reassess the company’s valuation. Notably, Canaccord Genuity reduced its price target for AngioDynamics following the updated EBITDA forecast, citing concerns about sustaining margin growth amid increasing operating expenses.
Conversely, the sustained double‑digit growth in the Med Tech business has been highlighted as a positive long‑term driver. The company’s ability to maintain robust sales in this high‑growth area, coupled with the introduction of new products like the AlphaVac and NanoKnife, positions it favorably against competitors in the interventional device market.
Outlook
AngioDynamics remains focused on expanding its product portfolio in the Med Tech space while navigating margin pressures. The company’s leadership has emphasized continued investment in research and development, particularly in thrombectomy and targeted therapy systems, as a key strategy for maintaining growth momentum.
Investors will likely watch for how the company balances its revenue expansion with the need to improve profitability. The forthcoming earnings reports and potential guidance revisions will provide further insight into AngioDynamics’ trajectory in the competitive health‑care equipment sector.
